Mamatha Siricilla, MD
Hematology/Oncology · Clovis
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 6
- Since medical school
- 20 years
- Graduated 2006
Offices
6 locations · Community Health Partners · Stanford Health Care
Hospitals listed: Clovis Community Medical Center · Community Regional Medical Center · Eden Medical Center · Marshall Medical Center · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Siricilla’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A148859 · Current
Licensed to practise in California · since 2017 · expires 2028-06-30 · University of Health Sciences, Vijayawada, Kakatiya Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Hematology
- American Board of Internal Medicine - Medical Oncology
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Clovis Community Medical CenterClovis, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 80% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.7 (12.1 to 17.7) · 421 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.692, Oct 2024 – Sep 2025
- Community Regional Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 211.21 (174.88 to 247.54) · 239 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.705, Oct 2024 – Sep 2025
- Eden Medical CenterCastro Valley, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.122, Oct 2024 – Sep 2025
- Marshall Medical CenterPlacerville, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Marshall Medical CenterPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Clovis Community Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 6 the same, 1 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.7 (12.1 to 17.7) · 421 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.692 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0.04 to 1.89) · 1,840 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.16 (0.86 to 1.45) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 217.06 (167.45 to 266.67) · 84 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.4 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14 · 507 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 798 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 336 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 3,771 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 8,649 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.08 to 0.46) · 9,146 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.46 (1.47 to 5.45) · 1,654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.19 (0.61 to 3.78) · 387 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.18 (0.7 to 3.66) · 1,578 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.47 (7.08 to 19.87) · 374 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.99 (1.37 to 8.61) · 379 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.04) · 405 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.8 (0.23 to 1.38) · 8,198 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 90 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.922 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.449 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.509 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 210 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -1.5 · 152 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 58.4 · 556 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18 · 769 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 802 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (4 to 7.4) · 421 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 91 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 93 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.8 to 15.6) · 2,398 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 720 cases | No different | Jan 2024 – Dec 2024 |
What patients said (441 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 80% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Community Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 211.21 (174.88 to 247.54) · 239 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.705 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.29 to 1.96) · 2,304 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.09 (0.87 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 116 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 445 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.2 · 399 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 582 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 3,744 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.5) · 11,052 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,566 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.64 to 5.01) · 3,139 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.08 (0 to 2.3) · 1,423 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.7 (0.52 to 2.88) · 3,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.85 (8.11 to 15.6) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.4 (3.81 to 8.98) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.35 (0.95 to 3.76) · 760 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.64 (0.16 to 1.11) · 10,254 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.817 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.031 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.837 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.81 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 258 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 689 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 37.4 · 202 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 35.2 · 543 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.2 · 434 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.3 · 552 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.6 to 7.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.3 to 15.4) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.4 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.6 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.9 (9.5 to 14.9) · 2,590 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 310 cases | No different | Jan 2024 – Dec 2024 |
What patients said (421 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Eden Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.122 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.89) · 819 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.46 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 137.41 (92.94 to 181.88) · 70 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 38 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 207 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 355 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 1,714 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,697 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.1 to 0.5) · 4,676 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 860 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.56 (0 to 3.24) · 251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.75 (1.17 to 4.32) · 818 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.76 (0 to 15.78) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.09 (2.08 to 10.1) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.64 (0.16 to 3.12) · 233 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.85) · 4,132 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 60 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.431 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.292 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.307 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.61 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 258 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 22.6 · 225 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2.4 · 367 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 390 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 58 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.6 to 17.4) · 68 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 205 cases | No different | Jan 2024 – Dec 2024 |
What patients said (431 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Marshall Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 4 the same, 0 worse of 4 measures. Readmissions: 1 better, 8 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.99) · 532 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.46 to 1.26) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 181.35 (122.12 to 240.58) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.7 · 116 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 52 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 245 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 368 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.9 · 171 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.3 · 1,441 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.3 (0.08 to 0.52) · 3,312 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 3,241 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.31 (1.98 to 6.63) · 546 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.32) · 122 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.13 (0.47 to 3.79) · 499 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.5 (0 to 16.61) · 124 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.8 (0.64 to 8.96) · 119 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.19 to 3.2) · 135 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.26 (0 to 1.13) · 2,770 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 40 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.56 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.1 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.9 · 263 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 9.2 · 381 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 384 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 7.1 (5 to 9.9) · 225 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.5 to 15) · 225 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5 · 43 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (9.1 to 15.1) · 1,577 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 545 cases | No different | Jan 2024 – Dec 2024 |
What patients said (540 patients answered, 21% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 45% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$158,869
Medicare paid this office $158,869 for 442 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 158 | $18,683 | $75 |
| Short return visit (20+ min) | 278 | $17,505 | $49 |
| Long return visit (40+ min) | 57 | $8,134 | $106 |
| New patient visit (45+ min) | 36 | $4,102 | $114 |
| New patient visit (60+ min) | 26 | $3,953 | $152 |
See all 8 services
| Return visit (30+ min) | 158 | $18,683 | $75 |
| Short return visit (20+ min) | 278 | $17,505 | $49 |
| Long return visit (40+ min) | 57 | $8,134 | $106 |
| New patient visit (45+ min) | 36 | $4,102 | $114 |
| New patient visit (60+ min) | 26 | $3,953 | $152 |
| Insertion of needle into vein for collection of blood sample | 32 | $484 | $9 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 35 | $479 | $8 |
| Blood test, comprehensive group of blood chemicals | 15 | $207 | $10 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy and aspiration of bone marrow sample for diagnosis | 17 | – | – | 12 | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
442 Original Medicare patients in 2024. Average age 76 · Under 65 6% · 85 and older 16% · Women 66% · Also on Medicaid 26% · Health risk score 1.98. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 73% · Cancer 50% · Chronic kidney disease 28% · Diabetes 26% · Coronary heart disease 22% · Atrial fibrillation 20% · COPD 19% · Heart failure 18% · Depression 17% · Stroke 11% · Dementia 5%.
The office billed $450,717, Medicare allowed $207,100 and paid $158,869; for 15,796 services of 56 kinds; $94,009 of it was for drugs given in the office and $64,860 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 442 | 15,796 | 76 | 1.98 | $450,717 | $158,869 |
| 2023 | 368 | 709 | 76 | 2.00 | $93,763 | $49,390 |
| 2022 | 476 | 1,290 | 76 | 1.91 | $148,562 | $80,769 |
| 2021 | 525 | 1,550 | 75 | 1.81 | $170,999 | $103,100 |
| 2020 | 466 | 1,343 | 75 | 2.00 | $135,916 | $90,589 |
| 2019 | 305 | 1,313 | 74 | 2.05 | $133,033 | $86,708 |
| 2018 | 277 | 1,004 | 74 | 1.77 | $93,173 | $61,720 |
| 2017 | 169 | 326 | 74 | 1.76 | $30,879 | $20,080 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Return visit (30+ min) | 134 | $17,017 | $69 |
| Short return visit (20+ min) | 218 | $11,832 | $44 |
| Long return visit (40+ min) | 66 | $11,371 | $108 |
| New patient visit (60+ min) | 39 | $4,936 | $127 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,593 | $100 |
| New patient visit (45+ min) | 16 | $1,239 | $77 |
2022: 8 services
| Short return visit (20+ min) | 378 | $38,805 | $48 |
| Return visit (30+ min) | 117 | $19,227 | $75 |
| Long return visit (40+ min) | 43 | $6,278 | $116 |
| New patient visit (60+ min) | 39 | $5,660 | $145 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $4,764 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $874 | $62 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 12 | $750 | $62 |
| Telephone medical discussion with physician, 5-10 minutes | 13 | $416 | $28 |
2021: 7 services
| Return visit (30+ min) | 245 | $42,946 | $68 |
| Short return visit (20+ min) | 358 | $29,540 | $49 |
| Long return visit (40+ min) | 57 | $9,258 | $94 |
| New patient visit (60+ min) | 59 | $8,547 | $145 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $5,814 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $2,695 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,675 | $152 |
2020: 7 services
| Return visit (30+ min) | 282 | $46,222 | $61 |
| Long return visit (40+ min) | 87 | $16,969 | $93 |
| Short return visit (20+ min) | 166 | $8,014 | $38 |
| New patient visit (60+ min) | 54 | $7,070 | $131 |
| New patient visit (45+ min) | 47 | $4,884 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $2,619 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,869 | $170 |
2019: 8 services
| Return visit (30+ min) | 203 | $47,788 | $60 |
| Long return visit (40+ min) | 64 | $14,660 | $89 |
| Short return visit (20+ min) | 136 | $6,931 | $36 |
| New patient visit (60+ min) | 47 | $6,151 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $3,978 | $85 |
| New patient visit (45+ min) | 29 | $2,956 | $102 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,304 | $165 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 15 | $1,040 | $61 |
2018: 8 services
| Return visit (30+ min) | 176 | $34,564 | $62 |
| Short return visit (20+ min) | 157 | $9,248 | $36 |
| New patient visit (60+ min) | 48 | $5,950 | $124 |
| New patient visit (45+ min) | 45 | $3,893 | $87 |
| Long return visit (40+ min) | 22 | $2,082 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $2,038 | $85 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 13 | $841 | $65 |
| New patient visit (30+ min) | 11 | $518 | $47 |
2017: 6 services
| Short return visit (20+ min) | 101 | $5,760 | $41 |
| Return visit (30+ min) | 54 | $4,989 | $63 |
| New patient visit (45+ min) | 18 | $1,796 | $100 |
| New patient visit (60+ min) | 13 | $1,773 | $136 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,608 | $85 |
| New patient visit (30+ min) | 15 | $926 | $62 |
Medicaid work
$7,304 in 2024
Medicaid paid $7,304 for 185 billed services this clinician did in 2024, up to 33 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 80 | $2,794 |
| Return visit (30+ min) | 41 | $2,019 |
| Service | 30 | $1,530 |
| Unlisted special service, procedure or report | 15 | $765 |
| Hospital outpatient clinic visit for assessment and management of a patient | 19 | $197 |
| 2024 | 185 | 5 | 33 | $7,304 |
| 2023 | 97 | 2 | 15 | $2,457 |
| 2022 | 282 | 2 | 35 | $8,725 |
| 2021 | 508 | 3 | 28 | $23,207 |
| 2020 | 374 | 3 | 25 | $8,116 |
| 2019 | 302 | 3 | 25 | $7,364 |
| 2018 | 204 | 2 | 18 | $6,681 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 57 | $1,562 |
| Return visit (30+ min) | 40 | $896 |
2022
| Short return visit (20+ min) | 256 | $8,671 |
| Hospital outpatient clinic visit for assessment and management of a patient | 26 | $54 |
2021
| Return visit (30+ min) | 187 | $11,814 |
| Short return visit (20+ min) | 227 | $11,367 |
| Hospital outpatient clinic visit for assessment and management of a patient | 94 | $26 |
2020
| Return visit (30+ min) | 186 | $6,286 |
| Short return visit (20+ min) | 58 | $1,397 |
| Hospital outpatient clinic visit for assessment and management of a patient | 130 | $433 |
2019
| Return visit (30+ min) | 240 | $6,937 |
| Short return visit (20+ min) | 12 | $336 |
| Hospital outpatient clinic visit for assessment and management of a patient | 50 | $90 |
2018
| Return visit (30+ min) | 191 | $6,681 |
| Hospital outpatient clinic visit for assessment and management of a patient | 13 | $0 |
Drugs they prescribed that Part D paid
$1,496,697
Pharmacies billed $1,496,697 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 8% of their Part D prescriptions (93 of 1,212) in 2024. Above the middle of the specialty; the typical hematology-oncology clinician is at 5%. Long-acting opioids: 13% of their opioid prescriptions.
1,068 generic and 144 brand-name prescriptions · $1,496,697 in drug cost · 24 antibiotic prescriptions to 18 people · 21 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 19 | $252,473 | $13,288 |
| Jakafi | 11 | $192,420 | $17,493 |
| Sprycel | 17 | $146,479 | $8,616 |
| Eliquis | 37 | $31,281 | $845 |
| Abiraterone Acetate | 20 | $25,447 | $1,272 |
See all 25 drugs
| Xtandi | 19 | $252,473 | $13,288 |
| Jakafi | 11 | $192,420 | $17,493 |
| Sprycel | 17 | $146,479 | $8,616 |
| Eliquis | 37 | $31,281 | $845 |
| Abiraterone Acetate | 20 | $25,447 | $1,272 |
| Letrozole | 163 | $3,838 | $24 |
| Anastrozole | 98 | $1,845 | $19 |
| Potassium Chloride | 43 | $1,825 | $42 |
| Ondansetron | 62 | $1,253 | $20 |
| Dexamethasone | 84 | $1,124 | $13 |
| Tamoxifen Citrate | 36 | $1,054 | $29 |
| Hydrocodone-Acetaminophen | 43 | $1,012 | $24 |
| Ondansetron Odt | 17 | $940 | $55 |
| Acyclovir | 39 | $664 | $17 |
| Prochlorperazine Maleate | 45 | $497 | $11 |
| Hydroxyurea | 23 | $457 | $20 |
| Oxycodone | 17 | $230 | $14 |
| Allopurinol | 17 | $219 | $13 |
| Olanzapine | 30 | $214 | $7 |
| Gabapentin | 28 | $150 | $5 |
| Loperamide | 17 | $122 | $7 |
| Tramadol | 11 | $112 | $10 |
| Montelukast | 12 | $88 | $7 |
| Prednisone | 28 | $80 | $3 |
| Pantoprazole | 12 | $39 | $3 |
Year by year
| 2024 | 1,212 | 296 | 8% (93) | 12% | $1,496,697 |
| 2023 | 904 | 188 | 4% (39) | 14% | $1,357,670 |
| 2022 | 1,334 | 209 | 3% (39) | None | $2,925,693 |
| 2021 | 1,405 | 211 | 4% (61) | 24% | $2,867,009 |
| 2020 | 1,210 | 170 | 6% (66) | 21% | $1,740,370 |
| 2019 | 949 | 124 | 9% (84) | 16% | $737,002 |
| 2018 | 644 | 102 | 7% (46) | 15% | $290,340 |
| 2017 | 114 | 35 | 13% (15) | 18% | $118,850 |
| 2016 | 17 | None | 0% (0) | None | $1,402 |
| 2014 | 21 | None | 0% (0) | None | $3,496 |
| 2013 | 21 | None | 0% (0) | 0% | $625 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Pomalyst | 15 | $360,533 | $24,036 |
| Imbruvica | 11 | $136,335 | $12,394 |
| Abiraterone Acetate | 22 | $36,692 | $1,668 |
| Eliquis | 34 | $22,995 | $676 |
| Letrozole | 112 | $8,294 | $74 |
| Anastrozole | 96 | $2,461 | $26 |
| Potassium Chloride | 57 | $1,692 | $30 |
| Acyclovir | 37 | $934 | $25 |
| Hydroxyurea | 21 | $879 | $42 |
| Hydrocodone-Acetaminophen | 24 | $701 | $29 |
| Dexamethasone | 32 | $650 | $20 |
| Ondansetron | 34 | $584 | $17 |
| Tamoxifen Citrate | 21 | $464 | $22 |
| Prochlorperazine Maleate | 36 | $378 | $11 |
| Loperamide | 20 | $370 | $19 |
| Gabapentin | 24 | $253 | $11 |
| Ondansetron Odt | 12 | $252 | $21 |
| Prednisone | 32 | $127 | $4 |
| Olanzapine | 13 | $97 | $7 |
| Montelukast | 17 | $92 | $5 |
| Furosemide | 11 | $27 | $2 |
2022: 29 drugs
| Pomalyst | 41 | $909,288 | $22,178 |
| Imbruvica | 31 | $430,794 | $13,897 |
| Revlimid | 15 | $294,911 | $19,661 |
| Ibrance | 19 | $289,205 | $15,221 |
| Venclexta | 16 | $192,502 | $12,031 |
| Xtandi | 13 | $191,976 | $14,767 |
| Eliquis | 53 | $36,852 | $695 |
| Abiraterone Acetate | 13 | $12,269 | $944 |
| Letrozole | 118 | $5,704 | $48 |
| Anastrozole | 145 | $3,045 | $21 |
| Hydroxyurea | 55 | $2,507 | $46 |
| Potassium Chloride | 70 | $1,691 | $24 |
| Dexamethasone | 45 | $1,527 | $34 |
| Acyclovir | 48 | $952 | $20 |
| Tamoxifen Citrate | 48 | $903 | $19 |
| Ondansetron | 36 | $827 | $23 |
| Olanzapine | 18 | $787 | $44 |
| Loperamide | 35 | $482 | $14 |
| Gabapentin | 52 | $402 | $8 |
| Prochlorperazine Maleate | 33 | $328 | $10 |
| Ondansetron Odt | 32 | $326 | $10 |
| Alendronate | 24 | $239 | $10 |
| Hydrocodone-Acetaminophen | 20 | $212 | $11 |
| Famotidine | 26 | $207 | $8 |
| Fludrocortisone Acetate | 12 | $183 | $15 |
| Prednisone | 32 | $114 | $4 |
| Furosemide | 15 | $84 | $6 |
| Lorazepam | 21 | $80 | $4 |
| Triamcinolone Acetonide | 11 | $58 | $5 |
2021: 28 drugs
| Ibrance | 51 | $698,027 | $13,687 |
| Pomalyst | 30 | $624,435 | $20,815 |
| Imbruvica | 37 | $506,773 | $13,697 |
| Revlimid | 13 | $201,305 | $15,485 |
| Eliquis | 90 | $54,298 | $603 |
| Anastrozole | 177 | $6,324 | $36 |
| Hydroxyurea | 58 | $2,819 | $49 |
| Dexamethasone | 61 | $1,766 | $29 |
| Letrozole | 66 | $1,664 | $25 |
| Tamoxifen Citrate | 28 | $990 | $35 |
| Ramelteon | 12 | $701 | $58 |
| Acyclovir | 20 | $670 | $34 |
| Potassium Chloride | 38 | $669 | $18 |
| Prochlorperazine Maleate | 52 | $593 | $11 |
| Famotidine | 35 | $590 | $17 |
| Hydrocodone-Acetaminophen | 30 | $527 | $18 |
| Risedronate | 11 | $499 | $45 |
| Ondansetron | 25 | $473 | $19 |
| Loperamide | 34 | $395 | $12 |
| Alendronate | 25 | $355 | $14 |
| Ondansetron Odt | 42 | $299 | $7 |
| Pantoprazole | 17 | $294 | $17 |
| Olanzapine | 20 | $258 | $13 |
| Gabapentin | 39 | $233 | $6 |
| Lorazepam | 28 | $153 | $5 |
| Furosemide | 23 | $80 | $3 |
| Tramadol | 13 | $65 | $5 |
| Prednisone | 17 | $42 | $2 |
2020: 27 drugs
| Ibrance | 30 | $395,190 | $13,173 |
| Imbruvica | 28 | $376,998 | $13,464 |
| Revlimid | 14 | $262,145 | $18,725 |
| Pomalyst | 13 | $248,698 | $19,131 |
| Eliquis | 79 | $44,116 | $558 |
| Anastrozole | 139 | $3,095 | $22 |
| Dexamethasone | 56 | $1,387 | $25 |
| Tamoxifen Citrate | 25 | $1,004 | $40 |
| Hydroxyurea | 30 | $984 | $33 |
| Ondansetron Odt | 65 | $814 | $13 |
| Prochlorperazine Maleate | 61 | $802 | $13 |
| Potassium Chloride | 25 | $743 | $30 |
| Letrozole | 15 | $718 | $48 |
| Ondansetron | 18 | $582 | $32 |
| Morphine Sulfate Er | 15 | $481 | $32 |
| Olanzapine | 39 | $434 | $11 |
| Loperamide | 39 | $431 | $11 |
| Famotidine | 26 | $388 | $15 |
| Hydrocodone-Acetaminophen | 24 | $359 | $15 |
| Nystatin | 16 | $346 | $22 |
| Gabapentin | 40 | $337 | $8 |
| Oxycodone | 12 | $256 | $21 |
| Lorazepam | 35 | $237 | $7 |
| Pantoprazole | 15 | $208 | $14 |
| Prednisone | 28 | $200 | $7 |
| Amlodipine Besylate | 27 | $78 | $3 |
| Alendronate | 13 | $73 | $6 |
2019: 23 drugs
| Ibrance | 28 | $352,783 | $12,599 |
| Imbruvica | 11 | $143,399 | $13,036 |
| Eliquis | 13 | $6,852 | $527 |
| Anastrozole | 110 | $2,253 | $20 |
| Dexamethasone | 49 | $1,593 | $33 |
| Potassium Chloride | 47 | $1,254 | $27 |
| Hydrocodone-Acetaminophen | 42 | $979 | $23 |
| Hydroxyurea | 12 | $601 | $50 |
| Morphine Sulfate Er | 21 | $547 | $26 |
| Risedronate | 13 | $459 | $35 |
| Acyclovir | 23 | $429 | $19 |
| Letrozole | 23 | $401 | $17 |
| Prochlorperazine Maleate | 51 | $316 | $6 |
| Lorazepam | 52 | $314 | $6 |
| Ondansetron | 18 | $278 | $15 |
| Gabapentin | 44 | $278 | $6 |
| Loperamide | 21 | $224 | $11 |
| Ondansetron Odt | 23 | $178 | $8 |
| Levofloxacin | 19 | $176 | $9 |
| Pantoprazole | 26 | $169 | $6 |
| Amlodipine Besylate | 29 | $121 | $4 |
| Furosemide | 14 | $95 | $7 |
| Cephalexin | 13 | $65 | $5 |
2018: 17 drugs
| Ibrance | 22 | $259,359 | $11,789 |
| Eliquis | 13 | $5,864 | $451 |
| Potassium Chloride | 30 | $4,443 | $148 |
| Anastrozole | 73 | $952 | $13 |
| Hydrocodone-Acetaminophen | 27 | $861 | $32 |
| Diphenoxylate-Atropine | 14 | $555 | $40 |
| Dexamethasone | 18 | $395 | $22 |
| Valacyclovir | 11 | $320 | $29 |
| Lorazepam | 52 | $250 | $5 |
| Gabapentin | 17 | $241 | $14 |
| Prochlorperazine Maleate | 46 | $233 | $5 |
| Ondansetron Odt | 40 | $210 | $5 |
| Loperamide | 17 | $192 | $11 |
| Allopurinol | 11 | $128 | $12 |
| Ondansetron | 21 | $108 | $5 |
| Famotidine | 21 | $76 | $4 |
| Tramadol | 11 | $47 | $4 |
Money from drug and device companies
$2,125 in 2025
| 2025 | 34 | 103 | None | $2,125 |
| 2024 | 31 | 111 | None | $2,165 |
| 2023 | 30 | 67 | None | $1,422 |
| 2022 | 23 | 78 | None | $1,049 |
| 2021 | 17 | 37 | None | $800 |
| 2020 | 15 | 27 | None | $462 |
| 2019 | 22 | 81 | None | $953 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Tagrisso | $401 | 13 payments
|
| Genentech USA | Polivy | $183 | 8 payments
|
| Novartis Pharmaceuticals | Scemblix | $140 | 6 payments
|
| Seagen | None | $100 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $96 | 4 payments
|
| Janssen Biotech | Talvey | $83 | 5 payments
|
See all 82 published payments
| Sobi | Meals · 2025-12-24 | Vonjo | $28 |
| Daiichi Sankyo | Meals · 2025-12-22 | Vanflyta | $21 |
| Caris MPI | Meals · 2025-12-16 | Mi Cancer Seek | $32 |
| Janssen Biotech | Meals · 2025-12-12 | Talvey | $15 |
| Incyte | Meals · 2025-12-12 | Monjuvi | $17 |
| Novartis Pharmaceuticals | Meals · 2025-12-10 | Fabhalta | $25 |
| Genmab U.S. | Meals · 2025-12-04 | Epkinly | $34 |
| Astellas Pharma US | Meals · 2025-12-04 | Cresemba | $25 |
| Abbvie | Meals · 2025-12-02 | Venclexta | $18 |
| Genentech USA | Meals · 2025-12-01 | Polivy | $29 |
| EMD Serono | Meals · 2025-11-20 | None | $17 |
| Servier Pharmaceuticals | Meals · 2025-11-18 | Tibsovo | $35 |
| Genzyme | Meals · 2025-11-12 | Cablivi | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-10 | Calquence | $26 |
| Novartis Pharmaceuticals | Meals · 2025-11-04 | Scemblix | $23 |
| Abbvie | Meals · 2025-10-23 | Venclexta | $18 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-22 | Calquence | $25 |
| Exelixis | Meals · 2025-10-20 | Cabometyx | $18 |
| SpringWorks Therapeutics | Meals · 2025-10-16 | Ogsiveo | $34 |
| Biocon Biologics | Meals · 2025-10-16 | Ogivri | $27 |
| Sobi | Meals · 2025-10-09 | Vonjo | $28 |
| Servier Pharmaceuticals | Meals · 2025-10-02 | Voranigo | $29 |
| Merck Sharp & Dohme | Meals · 2025-09-30 | Keytruda | $18 |
| Janssen Biotech | Meals · 2025-09-24 | Rybrevant | $14 |
| Regeneron Healthcare Solutions | Meals · 2025-09-24 | Lynozyfic | $19 |
| Jazz Pharmaceuticals | Meals · 2025-09-23 | Zepzelca | $23 |
| Genentech USA | Meals · 2025-09-22 | Polivy | $27 |
| Genzyme | Meals · 2025-09-15 | Ayvakit | $16 |
| Incyte | Meals · 2025-09-11 | Monjuvi | $24 |
| Merck Sharp & Dohme | Meals · 2025-09-04 | Keytruda | $26 |
| Novartis Pharmaceuticals | Meals · 2025-08-13 | Kisqali | $18 |
| Stemline Therapeutics | Meals · 2025-08-07 | Orserdu | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-31 | Calquence | $21 |
| Novartis Pharmaceuticals | Meals · 2025-07-25 | Scemblix | $15 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-23 | Tagrisso | $21 |
| Merck Sharp & Dohme | Meals · 2025-07-22 | Keytruda | $21 |
| Novartis Pharmaceuticals | Meals · 2025-06-26 | Kisqali | $25 |
| Caris MPI | Meals · 2025-06-24 | Mi Cancer Seek | $24 |
| EMD Serono | Meals · 2025-06-11 | None | $19 |
| Daiichi Sankyo | Meals · 2025-06-03 | Vanflyta | $17 |
| Genentech USA | Meals · 2025-04-03 | Polivy | $23 |
| Genentech USA | Meals · 2025-03-31 | Itovebi | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-27 | Lynparza | $27 |
| Janssen Biotech | Meals · 2025-03-20 | Erleada | $19 |
| Genentech USA | Meals · 2025-03-20 | Itovebi | $20 |
| Pfizer | Meals · 2025-03-20 | Inlyta | $13 |
| GlaxoSmithKline | Meals · 2025-03-18 | Ojjaara | $20 |
| Eisai | Meals · 2025-03-17 | Lenvima | $16 |
| Seagen | Education · 2025-03-14 | None | $100 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-13 | None | $29 |
| Rigel Pharmaceuticals | Meals · 2025-03-10 | Tavalisse | $30 |
| SpringWorks Therapeutics | Meals · 2025-03-06 | Ogsiveo | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-04 | Enhertu | $19 |
| Janssen Biotech | Meals · 2025-02-26 | Talvey | $17 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-26 | Advate | $21 |
| Immunocore | Meals · 2025-02-25 | Kimmtrak | $33 |
| Blueprint Medicines | Meals · 2025-02-24 | Ayvakit | $38 |
| Sobi | Meals · 2025-02-21 | Vonjo | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-19 | Lynparza | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-18 | Lynparza | $33 |
| Genentech USA | Meals · 2025-02-14 | Alecensa | $18 |
| Genentech USA | Meals · 2025-02-13 | Venclexta | $21 |
| Pfizer | Meals · 2025-02-11 | Inlyta | $26 |
| Eisai | Meals · 2025-02-10 | Lenvima | $29 |
| Agios Pharmaceuticals | Meals · 2025-02-06 | Pyrukynd | $39 |
| GlaxoSmithKline | Meals · 2025-02-04 | Ojjaara | $19 |
| Janssen Biotech | Meals · 2025-01-31 | Talvey | $19 |
| Blueprint Medicines | Meals · 2025-01-30 | Ayvakit | $25 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-29 | Fruzaqla | $20 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-28 | None | $34 |
| Novartis Pharmaceuticals | Meals · 2025-01-27 | Scemblix | $35 |
| Eisai | Meals · 2025-01-23 | Lenvima | $28 |
| Celgene | Meals · 2025-01-16 | Reblozyl | $25 |
| Lilly USA | Meals · 2025-01-14 | Verzenio | $29 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-13 | Opdualag | $29 |
| Merck Sharp & Dohme | Meals · 2025-01-10 | Keytruda | $31 |
| BeiGene USA | Meals · 2025-01-09 | Brukinsa | $14 |
| Genentech USA | Meals · 2025-01-07 | Itovebi | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-06 | None | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-05 | Tagrisso | $89 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-03 | Lynparza | $20 |
| Biocon Biologics | Meals · 2025-01-03 | Fulphila | $27 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,165
| AstraZeneca Pharmaceuticals LP | Enhertu | $358 | 13 payments
|
| Pfizer | Elrexfio | $185 | 11 payments
|
| Novartis Pharmaceuticals | Kisqali | $175 | 8 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $175 | 11 payments
|
| Genentech USA | Itovebi | $147 | 7 payments
|
| Takeda Pharmaceuticals U.S.A. | Fruzaqla | $95 | 4 payments
|
| Janssen Biotech | Rybrevant | $83 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $82 | 3 payments
|
| BeiGene USA | Brukinsa | $71 | 3 payments
|
| Incyte | Jakafi | $68 | 3 payments
|
| Ipsen Biopharmaceuticals | Onivyde | $61 | 2 payments
|
| Eisai | Lenvima | $61 | 3 payments
|
| Celgene | Reblozyl | $56 | 3 payments
|
| Astellas Pharma US | Xtandi | $50 | 2 payments
|
| Abbvie | Lupron Depot | $49 | 2 payments
|
| Lilly USA | Verzenio | $47 | 2 payments
|
| Array Biopharma | Braftovi | $46 | 2 payments
|
| Jazz Pharmaceuticals | Zepzelca | $37 | 1 payment
|
| EMD Serono | None | $31 | 1 payment
|
| Immunocore | Kimmtrak | $30 | 1 payment
|
| Stemline Therapeutics | Orserdu | $29 | 2 payments
|
| Blueprint Medicines | Ayvakit | $29 | 1 payment
|
| Servier Pharmaceuticals | Tibsovo | $28 | 1 payment
|
| Agios Pharmaceuticals | None | $28 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $27 | 1 payment
|
| Genzyme | Sarclisa | $25 | 1 payment
|
| Rigel Pharmaceuticals | Rezlidhia | $20 | 1 payment
|
| Coherus Biosciences | Udenyca | $18 | 1 payment
|
| GlaxoSmithKline | Jemperli | $17 | 1 payment
|
| Azurity Pharmaceuticals | Vivimusta | $17 | 1 payment
|
| Sobi | Doptelet | $17 | 1 payment
|
2023: $1,422
| Pfizer | Bosulif | $145 | 8 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $143 | 7 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $89 | 4 payments
|
| Incyte | Jakafi | $81 | 4 payments
|
| Novartis Pharmaceuticals | Piqray | $79 | 4 payments
|
| Celgene | Reblozyl | $72 | 4 payments
|
| Taiho Oncology | Lonsurf | $53 | 2 payments
|
| GlaxoSmithKline | Ojjaara | $53 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $51 | 2 payments
|
| Sobi | Doptelet | $50 | 2 payments
|
| Janssen Biotech | Erleada | $47 | 2 payments
|
| Seagen | Adcetris | $44 | 2 payments
|
| Genentech USA | Perjeta | $44 | 2 payments
|
| Stemline Therapeutics | Orserdu | $44 | 2 payments
|
| Eisai | Lenvima | $44 | 2 payments
|
| Array Biopharma | Lorbrena | $42 | 2 payments
|
| Amgen | Lumakras | $37 | 2 payments
|
| Jazz Pharmaceuticals | Zepzelca | $35 | 1 payment
|
| Daiichi Sankyo | Enhertu | $26 | 2 payments
|
| TerSera Therapeutics | Zoladex | $26 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $25 | 1 payment
|
| Lilly USA | Verzenio | $25 | 1 payment
|
| Genzyme | Sarclisa | $24 | 1 payment
|
| Ipsen Biopharmaceuticals | Onivyde | $23 | 1 payment
|
| PharmaEssentia USA | Besremi | $21 | 1 payment
|
| Mirati Therapeutics | Krazati | $21 | 1 payment
|
| Servier Pharmaceuticals | Tibsovo | $21 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $21 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $18 | 1 payment
|
| BeiGene USA | Brukinsa | $16 | 1 payment
|
2022: $1,049
| E.R. Squibb & Sons L.L.C. | Opdivo | $117 | 5 payments
|
| Seagen | Adcetris | $86 | 4 payments
|
| Genentech USA | Phesgo | $86 | 6 payments
|
| Eisai | Lenvima | $85 | 5 payments
|
| Amgen | Lumakras | $71 | 3 payments
|
| Blueprint Medicines | Ayvakit | $70 | 1 payment
|
| Abbvie | Venclexta | $67 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $61 | 3 payments
|
| Pfizer | Ibrance | $49 | 2 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $43 | 2 payments
|
| Acrotech Biopharma | Beleodaq | $38 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $37 | 2 payments
|
| Regeneron Healthcare Solutions | Libtayo | $36 | 1 payment
|
| Novartis Pharmaceuticals | Promacta | $33 | 2 payments
|
| Clovis Oncology | None | $23 | 1 payment
|
| Sobi | Doptelet | $22 | 1 payment
|
| Incyte | Jakafi | $21 | 1 payment
|
| Daiichi Sankyo | Injectafer | $20 | 1 payment
|
| Celgene | Onureg | $19 | 1 payment
|
| EMD Serono | None | $19 | 1 payment
|
| BeiGene USA | Brukinsa | $17 | 1 payment
|
| MorphoSys US | Monjuvi | $13 | 1 payment
|
| Janssen Biotech | Imbruvica | $12 | 1 payment
|
2021: $800
| Seagen | Adcetris | $167 | 6 payments
|
| Astellas Pharma US | None | $95 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $78 | 5 payments
|
| Amgen | Nplate | $72 | 4 payments
|
| Pfizer | Ibrance | $66 | 3 payments
|
| Gilead Sciences | Trodelvy | $60 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $37 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $36 | 2 payments
|
| Janssen Biotech | Rybrevant | $29 | 2 payments
|
| Novartis Pharmaceuticals | Kisqali | $29 | 2 payments
|
| Jazz Pharmaceuticals | Zepzelca | $25 | 1 payment
|
| GlaxoSmithKline | Zejula | $22 | 1 payment
|
| AbbVie | Venclexta | $21 | 1 payment
|
| Eisai | Lenvima | $18 | 1 payment
|
| Blueprint Medicines | Ayvakit | $17 | 1 payment
|
| Celgene | Reblozyl | $15 | 1 payment
|
| Acrotech Biopharma | Beleodaq | $14 | 1 payment
|
2020: $462
| E.R. Squibb & Sons L.L.C. | Opdivo | $98 | 5 payments
|
| Amgen | Prolia | $64 | 4 payments
|
| Janssen Biotech | Imbruvica | $63 | 4 payments
|
| Merck Sharp & Dohme | Lynparza | $40 | 2 payments
|
| Pfizer | Bosulif | $27 | 2 payments
|
| TOLMAR Pharmaceuticals | Eligard | $23 | 1 payment
|
| Novartis Pharmaceuticals | Mekinist | $19 | 1 payment
|
| Eisai | Lenvima | $19 | 1 payment
|
| AbbVie | Venclexta | $18 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $18 | 1 payment
|
| GlaxoSmithKline | Zejula | $17 | 1 payment
|
| Seagen | Adcetris | $15 | 1 payment
|
| Genzyme | Libtayo | $15 | 1 payment
|
| Roche Diagnostics | Dis Navify Software | $14 | 1 payment
|
| Secura Bio | Farydak | $12 | 1 payment
|
2019: $953
| Amgen | Kanjinti | $139 | 11 payments
|
| Pfizer | Ibrance | $131 | 15 payments
|
| Janssen Biotech | Erleada | $127 | 23 payments
|
| Astellas Pharma US | None | $108 | 3 payments
|
| Novartis Pharmaceuticals | Promacta | $65 | 4 payments
|
| Genentech USA | Venclexta | $49 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $45 | 3 payments
|
| Alexion Pharmaceuticals | Ultomiris | $44 | 2 payments
|
| Seattle Genetics | Adcetris | $32 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Sprycel | $27 | 2 payments
|
| Merck Sharp & Dohme | Dificid | $25 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Vitrakvi | $25 | 1 payment
|
| Exelixis | Cabometyx | $24 | 1 payment
|
| Incyte | Jakafi | $19 | 1 payment
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $16 | 1 payment
|
| Daiichi Sankyo | Injectafer | $15 | 1 payment
|
| AbbVie | Venclexta | $14 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $12 | 1 payment
|
| Taiho Oncology | Lonsurf | $12 | 1 payment
|
| Verastem | Copiktra | $11 | 1 payment
|
| Janssen Pharmaceuticals | Erleada | $9 | 1 payment
|
| Clovis Oncology | Rubraca | $2 | 1 payment
|
Professional record
- NPI
- 1487967576
- Licence
- CA A148859California A148859: Current · expires 2028-06-30
- Group
- Community Health Partners · Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0000X (207RH0000X); Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 3581 Palmer Dr Ste 400, Cameron Park, CA, 95682
- NPI first listed
- 2010-07-19
- NPI last updated
- 2024-10-08
- NPI record certified
- 2024-10-08
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 20055 Lake Chabot Rd Ste 130, Castro Valley, CA, 94546